RELAPSED/REFRACTORY MULTIPLE MYELOMA

This early-phase study is testing a new cell therapy called IMV102 in patients with multiple myeloma that has returned or stopped responding to other treatments. The research will check if the treatment is safe and if it helps control the cancer. About 30 patients who have alread…

This is an early-phase study testing a new type of personalized immune cell therapy called CT0596 CAR-T. It aims to see if this treatment is safe and effective for adults with multiple myeloma or plasma cell leukemia that has come back or stopped responding to other treatments. T…

This study is testing a new drug called sonrotoclax for people with multiple myeloma that has come back or stopped responding to other treatments. Researchers want to see if sonrotoclax is safe and effective when given alone or combined with other standard myeloma drugs. The tria…

This early-stage study is testing the safety and best dose of a new cell therapy called CB-011 for people with multiple myeloma that has come back or stopped responding to other treatments. The therapy uses CRISPR gene-editing technology to create 'off-the-shelf' immune cells des…

This study is testing a new drug called LBL-034 in people with multiple myeloma that has returned or isn't responding to other treatments. The first part aims to find a safe and tolerable dose. The second part will see how well the drug works at shrinking the cancer and keeping i…

This Phase 3 trial is testing whether a new, advanced cell therapy called AZD0120 works better than current standard drug combinations for people with multiple myeloma that has come back after treatment. The therapy involves modifying a patient's own immune cells to attack two sp…

This is the first study in people testing a new drug called ISB 2001 for multiple myeloma that has returned or stopped responding to all standard treatments. Researchers will give increasing doses to about 200 participants to find a safe amount and see if it helps control the can…

This study is testing if a combination of two drugs, elranatamab and isatuximab, can help control multiple myeloma that has returned or stopped responding to other treatments. It will enroll 30 adults whose cancer has progressed after at least two prior therapies. The goal is to …

This study is testing whether a new drug called cemsidomide, when given with a standard steroid (dexamethasone), can help control multiple myeloma that has come back or stopped responding to other treatments. It is for adults who have already tried at least three different types …

This study aims to observe and document how standard treatments for relapsed multiple myeloma perform in real-world clinical practice, not in a controlled trial. It will follow 300 patients who have already tried several other treatments, tracking how well the treatments work, th…